Median baseline hematological and inflammatory values
| Marker | All patients | Response to sarilumab | No response to sarilumab |
| (median values) | N=15 | N=10 | N=5 |
| Baseline IL-6 | 61.9 pg/mL (range 5.2–1000) | 56.6 pg/mL (range 5.2–81.5) | 213 pg/mL (range 60.5–1000) |
| < ULN, n (%) | 0 (0) | 0 (0) | 0 (0) |
| ≥ ULN, n (%) | 11 (73.3) | 7 (70) | 4 (80) |
| > 10× ULN, n (%) | 8 (53.3) | 4 (40) | 4 (80) |
| > 20× ULN, n (%) | 2 (13.3) | 0 (0) | 2 (20) |
| NA, n (%) | 4 (26.7) | 3 (30) | 1 (20) |
| Baseline ALC | 740/μL (range 160–1490) | 755/μL (range 160–1490) | 530/μL (range 460–1100) |
| < 800, n (%) | 11 (73.3) | 7 (70) | 4 (800) |
| ≥ 800, n (%) | 4 (26.7) | 3 (30) | 1 (20) |
| Baseline d-dimer | 1151 ng/ml (range 200–4250) | 1127 ng/ml (range 200–2907) | 1884 ng/ml (range 464–4250) |
| < ULN, n (%) | 2 (13.3) | 2 (20) | 0 (0) |
| ≥ ULN, n (%) | 9 (60) | 6 (60) | 3 (60) |
| > 2× ULN, n (%) | 8 (53.3) | 6 (60) | 2 (40) |
| > 5× ULN, n (%) | 5 (33.3) | 3 (30) | 2 (40) |
| NA, n (%) | 4 (26.7) | 2 (20) | 2 (20) |
| Median Baseline PLT | 306 x109/μL (range127–535) | 291 x109/μL (range127–393) | 320 x109/μL (range 138–535) |
| < ULN, n (%) | 14 (93.3) | 10 (100) | 4 (80) |
| ≥ ULN, n (%) | 1 (6.7) | 0 (0) | 1 (20) |
| Baseline CRP | 15 mg/dl (range 1.1–30.5) | 12.9 mg/dl (range 3.5–27.8) | 29.5 mg/dl (range 1.1–30.5) |
| < ULN, n (%) | 0 (0) | 0 (0) | 0 (0) |
| ≥ ULN, n (%) | 12 (80) | 9 (90) | 3 (60) |
| > 10× ULN, n (%) | 8 (53.3) | 6 (60) | 0 (0) |
| > 20× ULN, n (%) | 4 (26.7) | 2 (20) | 0 (0) |
| NA, n(%) | 3 (20) | 1 (10) | 2 (40) |
| Median NLR | 14.6 (range 1.8–25.1) | 9.5 (range 1.9–22.7) | 19.5 (range 14.6–25.2) |
| NLR < 5, n (%) | 2 (13.3) | 2 (20) | 0 (0) |
| NLR ≥ 5, n (%) | 13 (86.7) | 8 (80) | 5(100) |
| NLR ≥ 10, n (%) | 10 (66.6) | 5 (50) | 5 (100) |
ALC, Absolute Lymphocte Count; CRP, C reactive protein; IL-6, interleukin 6; NA, Not Available; NLR, neutrophil to lymphocyte ratio; PLT, platelet; ULN, upper limit of normal.